Clinical trials: Episodic Migraine
Resistant Migraine, Chronic Migraine Headache
A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant…
- Conditions
- Resistant Migraine, Chronic Migraine Headache, Headache (Migraine), Headache, Cluster
- Trial name
- RECLAIM-II (NCT07719608)
- Testing
- Neurostimulator
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Salvia BioElectronics
Migraine
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
- Trial name
- NCT02629861
- Testing
- Fremanezumab
- Where
- 275 sites in United States, Canada and 7 more
- Volunteers
- 875 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
Migraine is a very common, neurological disorder, characterized by recurrent episodes of headache, potential progression to more frequent and severe attack patterns, and associated symptoms.
- Trial name
- COMIG (NCT04114630)
- Testing
- erenumab 70mg/mL
- Where
- 27 sites in Spain
- Sponsor
- Novartis Pharmaceuticals
Migraine, Episodic Migraine
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
The purpose of this study is to assess whether galcanezumab is superior to rimegepant in the prevention of migraine in participants with episodic migraine. The study duration will be approximately 6 months.
- Trial name
- CHALLENGE-MIG (NCT05127486)
- Testing
- Galcanezumab, Rimegepant
- Where
- 77 sites in United States
- Volunteers
- 580 people
- Sponsor
- Eli Lilly and Company
Migraine
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-1 (NCT02614183)
- Testing
- Galcanezumab
- Where
- 95 sites in United States, Canada and 1 more
- Volunteers
- 862 people
- Sponsor
- Eli Lilly and Company
Migraine, Episodic Migraine
Transnasal Cooling for Migraine
This is a prospective, double-blind, sham-controlled, randomized study to assess the safety, tolerability, and optimal dose of the COOLSTAT Transnasal Thermal Regulating Device for acute treatment of migraine.
- Conditions
- Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT04936061
- Testing
- CoolStat active device
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- CoolTech LLC
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
Migraine With or Without Aura
The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
- Trial name
- NCT03194555
- Testing
- Low-Dose Naltrexone and Acetaminophen Combination
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period.
- Trial name
- NCT01125774
- Testing
- Telcagepant
- Volunteers
- 4,548 people
- Sponsor
- Merck Sharp & Dohme LLC
Episodic Migraine
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have…
- Trial name
- NCT03927144
- Testing
- AMG334, Oral Prophylactic
- Where
- 112 sites in United States, Argentina and 16 more
- Volunteers
- 621 people
- Sponsor
- Amgen
Migraine, Headache
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
The purpose of this study is to determine whether Topiramate is effective in preventing the development of chronic daily headache among patients with episodic migraine headaches.
- Conditions
- Migraine, Headache, Classic Migraine, Common Migraine
- Trial name
- NCT00212810
- Testing
- Topiramate
- Volunteers
- 385 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Migraine
Probiotics for the Prophylaxis of Migraine
This study aims to understand the efficacy of two probiotic interventions as prophylaxes of migraine symptoms in individuals diagnosed with episodic migraine.
- Trial name
- MIGR_PRO2 (NCT04305522)
- Testing
- Probiotic 1, Probiotic 2
- Where
- 2 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Biopolis S.L.
Migraine
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine.
- Trial name
- OASIS(EM) (NCT03836040)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 457 people
- Sponsor
- Amgen
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine.
- Trial name
- REBUILD-1 (NCT03432286)
- Testing
- Galcanezumab
- Where
- 73 sites in United States, Denmark and 8 more
- Volunteers
- 533 people
- Sponsor
- Eli Lilly and Company
Episodic Migraine, Migraine With Aura
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment…
- Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT06051604
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- CoolTech LLC
Episodic Migraine
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
The purpose of this study is to determine if AMG 334 is effective in treating migraines in patients who have failed other preventive migraine treatments.
- Trial name
- NCT03096834
- Testing
- AMG334 (70 mg) Pre-Filled Syringe (PFS)
- Where
- 59 sites in Australia, Austria and 14 more
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- JPN PIVOTAL (NCT05861427)
- Testing
- Atogepant
- Where
- 48 sites in Japan
- Volunteers
- 524 people
- Sponsor
- AbbVie
Migraine Disorders
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
- Trial name
- PROMISE 1 (NCT02559895)
- Testing
- ALD403
- Where
- 87 sites in United States, Georgia
- Volunteers
- 898 people
- Sponsor
- Alder Biopharmaceuticals, Inc.